Euda Health Holdings Limited - Ordinary Shares (EUDA) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor
NEWS SCORE
54/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
28
Weak based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$11.95
Trend Context
Mixed / range
Latest briefing
What's happening with EUDA
globenewswire.com1 Jun 2026
EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask
SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) ("EUDA" or the "Company"), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced it is expanding the Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask ("Regenixé Mask"), a beauty product developed by Chemokine Pte Ltd ("Chemokine").
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com28 Apr 2026
EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development
SINGAPORE, April 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced that Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of cellular therapies in China, has received official approval under the 2025 Shenzhen Key Industry R&D Program.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com27 Apr 2026
EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities
Singapore, April 27, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" and the "Company") received a written notice (the "MVLS Notice") from Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities ("MVLS") of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2).
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Earnings news
EUDA earnings headlines
This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.
